|
KR20170100656A
|
|
Heterocyclylalkane derivatives as modulators of mGLuR5 receptors and uses thereof
|
|
CA2800930A1
|
|
Novel spiroheterocyclic compounds as mglu5 antagonists
|
|
EP2477981A1
|
|
Heterocyclic mglu5 antagonists
|
|
US2010317630A1
|
|
Novel heterocyclic compounds as mglu5 antagonists
|
|
CN102076664A
|
|
A process for producing lercanidipine HCL form v
|
|
KR20100052507A
|
|
Novel heterocyclic compounds as mglu5 antagonists
|
|
UA104128C2
|
|
Novel heterocyclic compounds as mglu5 antagonists
|
|
WO2008077599A1
|
|
COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH α2δ LIGANDS AND NSAIDS
|
|
AU2007280407A1
|
|
Process for preparing amorphous lercanidipine hydrochloride
|
|
US2007270436A1
|
|
Novel amino- and imino-alkylpiperazines
|
|
WO2007088063A1
|
|
Acid addition salts of n-{3-[4-(2-methoxyphenyl)-l-piperazinyl]-propyl}-7-oxo-5- trifluoromethyl-7h-thieno[3,2-b]pyran-3-carboxamide
|
|
CA2597992A1
|
|
Lercanidipine free base
|
|
AR052918A1
|
|
LERCANIDIPINE AMORFO CHLORHYDRATE
|
|
CN101035518A
|
|
Lercanidipine capsules
|
|
TW200616681A
|
|
Lercanidipine capsules
|
|
TW200613275A
|
|
Lercanidipine salts
|
|
US2005260253A1
|
|
Transmucosal gel formulations
|
|
US2005165025A1
|
|
Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists
|
|
US2005101640A1
|
|
Lisinopril/lercanidipine combination therapy
|
|
US2004198789A1
|
|
Lercanidipine/ARB/diuretic therapeutic combinations
|
